Gentbrugge — Trinean, the leading provider of microfluidic spectrophotometry

platforms, today announced that it appointed Mr. Chris van Ingen as independent board

member.

“We are very pleased to be working with Chris van Ingen,” comments Philippe Stas, CEO of

Trinean. “His broad experience in the life science instrumentation field will be valuable to

bring Trinean in its next phase of expansion.”

“Trinean’s fully integrated instrumentation platform offers excellent opportunities to automate

and simplify many life sciences workflows”, Chris van Ingen adds, “and I am looking forward

working with the Trinean board and management team.”

Currently, Chris is a director of the Bruker corporation, the Promega corporation and

ProteinSimple corporation. Previously, Mr. van Ingen was president of Agilent Technologies’

Bio-Analytical Measurement Group. Between 1977 and 2001, Mr. van Ingen held several

senior management positions at Hewlett Packard, including Vice President of Sales and

Marketing of the Chemical Analysis group.

About Trinean

Trinean is a Belgium based instrumentation company, bringing micro-volume molecular

spectroscopy to the next level by combining best in class analytical software with a highly

standardized read-out platform. Founded in 2006 as a spin-out of the Ghent University,

Belgium and Imec Leuven, Belgium, the company commercializes two instruments, the

Xpose for ‘Touch & Go’ biomolecule quantification and the DropSense96®, analyzing up to

96 samples, using microfluidic chips for standardized sample analysis ( DropPlates and

Xpose Slides). The Trinean platform is complemented with a software toolbox for improved

data interpretation and lab-automation.

For more information about Trinean, visit https://www.trinean.com

Further information:

Trinean N.V.

ir. Philippe Stas

Chief Executive Officer

Dulle Grietlaan 17/3

B-9050 Gent – Belgium

Tel.: +32-9-272.75.35

Fax.: +32-9-272.75.39

info@trinean.com